News

Christa Wirthumer-Hoche, PhD, head of the Austrian Medicines and Medical Devices Agency, has been elected Vice-Chair of the European Medicines Agency (EMA) by the Management Board for a three-year period.

Whether we are referring to CSRs or to IPD, the personal information of trial participants needs to be de-identified prior to release. This article will describe the available methods for de-identifying clinical trial data, and the relative strengths and weaknesses of each.

To celebrate 20 years since its opening, the European Medicines Agency (EMA) organized a one-day meeting this week. Called “Science, Medicines, Health: Patients at the heart of future innovation”, the invitation-only event in London focused on the EMA’s future role